|
|
|
|
|
|
Bench Scientists’ & Modellers’ Discussions
on Discovery Tools & Modeling |
InterAction Meeting Session, Bryn Mawr, Philadelphia, USA,
Wednesday, 18 October 2006
chaired by Jim Wikel (Coalesix) Bio.... | |
Overview
In this session a panel of experimental and computational chemists will discuss their experiences in using computational modeling methods in drug discovery. They will discuss where the methods and software are having success, and where current methods are not yet meeting their needs, are failing or have challenges or complications. Short presentations on drug discovery experiences will be used to seed discussion of cheminformatics-driven medicinal chemistry and lead optimization and conversations on where new developments could aid improvement in practice and tools.
Panel: Osman F. Güner (Turquoise Consulting), James Arnold (AstraZeneca), Phil Edwards (AstraZeneca), Pete Connolly (Johnson & Johnson PRD), Michael Farnum (Johnson & Johnson PRD), Jim Wikel (Coalesix)
Panel Presentations & Experiences for Discussion
Osman F. Güner (Turquoise Consulting), Computational Tools for Medicinal Chemists Abstract & Bio....
James Arnold (AstraZeneca), Use of computational techniques in the discovery of low molecular weight non-peptidic beta-secretase inhibitors: Application of fragment screening and structure-based design to identify and progress millimolar affinity hits to sub-micromolar leads Abstract & Bio....
Phil Edwards (AstraZeneca), The Discovery of low molecular weight non-peptidic beta-secretase inhibitors: Application of fragment screening and structure-based design to identify and progress millimolar affinity hits to nanomolar leads Abstract & Bio....
Pete Connolly (Johnson & Johnson PRD), New Tools for Structure-Activity Relationship Visualization: Applications to Drug Discovery Abstract & Bio....
Michael Farnum (Johnson & Johnson PRD), Applying Chemical Intelligence to support Drug Discovery Researchers Abstract & Bio....
Jim Wikel (Coalesix), Man, Machine & Drug Design Abstract & Bio....
|
|
|
|
|
|
|
|
|
|
